ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces publication of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results